Catalio Capital Management, LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Catalio Capital Management, LP reported 33 stock positions worth $457.1 million. Its top holding was Becton Dickinson and (BDX) at 7.4% of the portfolio, followed by Ascendis Pharma A/S (ASND, 6.5%) and Bristol-Myers Squibb (BMY, 6.2%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001958125
- Portfolio Value
- $457.1M (Q4 2024)
- SEC Filing
- 0001958125-25-000002 ↗ filed Feb 14, 2025
Holdings Value
Holdings 33 stocks · $457.1M
| BDX Becton Dickinson and Co. | 7.38% | 148,615 | $33.7M | — |
| ASND Ascendis Pharma A/S | 6.49% | 215,587 | $29.7M | — |
| BMY Bristol-Myers Squibb Co. | 6.18% | 499,151 | $28.2M | — |
| SWTX Springworks Therapeutics Inc. | 6.04% | 764,668 | $27.6M | — |
| BPMC Blueprint Medicines Corp. | 5.43% | 284,654 | $24.8M | — |
| EW Edwards Lifesciences Corp. | 5.39% | 333,144 | $24.7M | — |
| BBIO Bridgebio Pharma Inc. | 5.39% | 898,458 | $24.7M | — |
| LIVN Livanova PLC | 5.19% | 512,447 | $23.7M | — |
| SEPN Septerna Inc. | 5.13% | 1,024,245 | $23.5M | — |
| CYTK Cytokinetics Inc. | 4.71% | 457,587 | $21.5M | — |
| NVST Envista Holdings Corp. | 4.30% | 1,019,529 | $19.7M | — |
| VCYT Veracyte Inc. | 4.25% | 490,547 | $19.4M | — |
| ISRG Intuitive Surgical Inc. | 4.21% | 36,910 | $19.3M | — |
| EXAS Exact Sciences Corp. | 3.80% | 309,103 | $17.4M | — |
| DNTH Dianthus Therapeutics Inc. | 3.64% | 763,471 | $16.6M | — |
| QURE Uniqure NV | 3.48% | 901,973 | $15.9M | — |
| GPCR Structure Therapeutics Inc. | 3.38% | 569,395 | $15.4M | — |
| MASI Masimo Corp. | 3.16% | 87,377 | $14.4M | — |
| IRON Disc Medicine Inc. | 2.49% | 179,815 | $11.4M | — |
| ADMA Adma Biologics Inc. | 1.92% | 512,724 | $8.8M | — |
| NARI Inari Medical Inc. | 1.48% | 132,545 | $6.8M | — |
| BSX Boston Scientific Corp. | 1.42% | 72,925 | $6.5M | — |
| KROS Keros Therapeutics Inc. | 1.41% | 407,292 | $6.4M | — |
| TARA Protara Therapeutic Inc. | 1.26% | 1,088,691 | $5.7M | — |
| MERSANA THERAPEUTICS INC | 0.53% | 1,705,036 | $2.4M | — |
| KYTX Kyverna Therapeutics Inc. | 0.48% | 586,909 | $2.2M | — |
| MGX Metagenomi Therapeutics Inc. | 0.42% | 528,993 | $1.9M | — |
| KPTI Karyopharm Therapeutics Inc. | 0.35% | 2,334,375 | $1.6M | — |
| ZBIO Zenas Biopharma Inc. | 0.34% | 187,184 | $1.5M | — |
| HYPR Hyperfine Inc. | 0.15% | 760,035 | $669K | — |
| GUTS Fractyl Health Inc. | 0.10% | 214,236 | $441K | — |
| ATAIBECKLEY INC filed as ATAI LIFE SCIENCES NV | 0.06% | 196,858 | $262K | — |
| SENSEI BIOTHERAPEUTICS INC | 0.03% | 294,374 | $144K | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $532.1M | AVLN, JNJ, GILD, BBIO, SNDX |
| Q1 2026 | 41 | $478.7M | DNTH, BBIO, ASND, BMY, SNDX |
| Q4 2025Amended | 45 | $565.8M | GILD, BMY, BSX, BBIO, LLY |
| Q3 2025 | 38 | $540.9M | LLY, ABBV, BBIO, ISRG, ASND |
| Q2 2025 | 40 | $476.9M | LLY, BBIO, SLNO, ASND, ISRG |
| Q1 2025 | 35 | $403.4M | BDX, SWTX, BBIO, EW, ASND |
| Q4 2024 | 33 | $457.1M | BDX, ASND, BMY, SWTX, BPMC |